Performance In Initiating Report Qtr 3 Oct-Dec

	_		ting Report Qtr 3 Oct-Dec																										
Research Ethi Committee	s Integrati	Submissi n Type	io Name of Trial	First Participant Recruited?	Date of First Participant	Duration between	Duration between  Date Site Confirme	Duration d between	Date Study	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed	Date Site Confirmed	Non- Confirmat	Date Site t Ready To	DateAdded Dat ed	eAmend A - Pern	missions	B - C - Closed Suspended by	d D - Sponsor	E - Staff F availabilit p	- No atients	G - No patients	H - Contracti	I - Rare J - Other diseases	Reasons for Delay	Comments	Reasons for delay correspond to:
Reference	Research	١ .			Recruited	Date Site	and First Participan	t Date Site	Initiated				By Sponsor		ion Status			dela	yed/de	by sponsor sponsor			een	consente					
Number	Applicat n System					Selected and Date Site	d Recruited	Selected and First										nied	1					d					
	Number					Confirmed		Participant	t																				
17/WM/0371	228033	HRA	INTEREST: Intervention to	Yes	09/03/2018	13	43	Recruited 56		31/07/2017	12/01/2018	02/11/2017	25/01/2018	25/01/2018	Please	29/01/2018	12/04/2018 25/	01/2019						Υ			G - No patients	A large pool of	Neither
		Approva	I reduce sitting time in older												Select												consented	patients to approach,	
			adults undergoing orthopaedic surgery: a																									but many do not want to be involved	
			feasibility study								/ /																		
18/SC/0095	235876	HRA Approva	BREEZE-AD4 - Baricitinib in moderate to severe atopic			31				06/09/2017	09/04/2018	05/04/2018	26/04/2018	10/05/2018	Please Select	14/05/2018	20/07/2018 25/	01/2019						Y			G - No patients consented	Delays with First patient recruited due	NHS Provider
			dermatitis																									to reason G	
			A Phase 3, Multicenter, Double-Blind, Randomized.																										
			Placebo-Controlled Study	'																									
			Evaluating the Safety and Efficacy of Barcitinib in																										
			Combination with Topical																										
			Corticosteroids in Patients with Moderate to Severe																										
			Atopic Dermatitis who have	e																									
			Experienced Failure to Cyclosporine or are																										
			Intolerant to, or have																										
			Contraindication to																										
			Cyclosporine																										
18/LO/0813	247105	HRA	IDDSI Level 2 ONS study -	No		203				01/02/2019	06/04/2019	28/08/2018	16/07/2018	26/10/2019	Please	26/10/2019	20/07/2018 25/	01/2019 V									A - permissions	Set up delayed due to	Sponsor
18/10/0813	247103	Approva		INO		203				01/02/2018	00/04/2016	26/06/2016	10/07/2018	20/10/2018	Select	20/10/2018	20/07/2018 23/	01/2019									delayed	Sponsor, as changes	эронзон
			An evaluation of the tolerance, compliance,																									required by REC/HRA. new SIV date =	
			acceptability and safety of a	а																								29.08.18; cancelled,	
			new oral nutritional																									likely to be October	
			supplement in dysphagic patients																									2018 with a new CRA	
14/EE/1293	164389	HRA Approva	C-STICH  The Cerclage Suture Type	Yes	23/11/2018		136	197		11/01/2018	10/05/2018	10/08/2016	11/06/2018	10/07/2018	Please Select	04/10/2018	20/07/2018 25/	01/2019			Υ	Y			Y		D - Sponsor Delays E - Staff availability H	delays with sponsor sending the contract,	Both
		Арргоча	for an Insufficient Cervix												Select												contracting delays	Site delays due to R&D	
			and its effect on Health outcomes																									director on leave to be able to sign contract.	
			outcomes																									Due to change over of	
																												study centre staff, the	
																												green light was not issued until	
																												04/10/2018.	
			GBS2																								A - permissions		
			Accuracy of a rapid intrapar	г																							delayed	Delays at site	
16/WM/0036	100476	HRA	tum test for maternal group B streptococcal colonisatio							01 /05 /2010	00/06/2016	23/08/2016	01/11/2018	06/11/2010	Please	10/12/2010	20/07/2018 25/	04 /2040 V								l ,		regarding	NHS Provider
10/ WW/0030	180476	Approva	n and its potential to reduce							01/06/2018	06/06/2018	23/08/2016	01/11/2016	06/11/2016	Select	10/12/2018	20/07/2018 25/	01/2019 1								ľ		microbiology support for the study	NH3 Provider
			antibiotic usage in mothers with risk factors.	:																								for the study	
16/NS/0106	212541	HRA	RAACENO - Reducing	No		25				24/11/2016	24/07/2018	04/04/2017	03/08/2018	28/08/2018	Please	31/08/2018	18/10/2018 25/	01/2019 V									A - permissions	Delays with Trust IT	NHS Provider
10/143/0100	212341	Approva	I Asthma Attacks in Children							24/11/2010	24/07/2010	04/04/2017	03/00/2010	20,00,2010	Select	51/00/2010	10/10/2010 23/	31,2013									delayed	approval of App to be	i i i i i i i i i i i i i i i i i i i
			using Exhaled Nitric Oxide as a biomarker to inform																									installed for use of smart inhalers	
			treatment strategy - a																									Siliai Cilliaiei S	
			randomised trial																										
17/YH/0120	208838		DISC - Dupuytren's	No		131				13/11/2017	01/08/2018	25/05/2017	03/12/2018	10/12/2018		21/12/2018	18/10/2018 25/	01/2019				Y					E - Staff availability	Delays due to	NHS Provider
		Approva	I Interventions Surgery vs Collagenase												Select													pharmacy capacity	
15/NI/0161	184748	HRA	EASI-SWITCH v1.0 - Early	No		75				22/05/2018	26/07/2018	03/08/2016	01/11/2018	09/10/2018		01/11/2018	18/10/2018 25/	01/2019			Υ						D - Sponsor Delays	date missing for	Sponsor
		Approva	I switch to oral antibiotic therapy in patients with low												Select													Sponsor to confirm site, expected early	
			risk neutropenic sepsis																									Nov. CTA has been	
																												sent to sponsor for signature. Site	
																												selected in July 2018	
																												however sponsor did not want to arrange	
																												SIV until Sept/Oct	
17/EE/0368	213669	HRA	STRESS L - Study into the	No						12/04/2018	22/06/2018	10/11/2017			Please		18/10/2018 25/	01/2019				Υ					E - Staff availability	2018. Delays due to	NHS Provider
		Approva	I Reversal of Septic Shock												Select													pharmacy capacity.	
			with Landiolol (Beta Blockade)																									Site requested that SIV delayed.	
18/SC/0210	239572		EFFICACY AND SAFETY OF			10				13/10/2017	14/09/2018	02/08/2018	14/09/2018	24/09/2018		23/10/2018	25/01/2019 25/	01/2019			Υ	Υ						delays in set-up due to	Both
		Approva	1 PF-04965842 200 MG AND 100 MG QD												Select												Staff availability	pharmacy staff shortage and sponsor	
			MONOTHERAPY IN																									not completing IT &	
			SUBJECTS WITH AD																									PPQ forms for equipment. Also	
																												sponsor delays as	
																												awaiting EC confirmation to	
																												approve extension	
																												study - B7451015. 18/10/2018 IIP	
																												approval received by	
																												sponsor.	
18/EM/0281	251974	HRA	ECZTEND - Tralokinumab in	Vos	13/12/2018	14	15	29		24/05/2019	14/11/2019	14/11/2018	14/11/2019	28/11/2019	Please	28/11/2019	Unknown Unk	nown 25/0	11/2010	25/01/2019									1
-5,, 0231		Approva	I moderate-severe AD	_	,, 2013					.,,	,, 2016	.,, 2010	., ., .,	,, 2010	Select	-0, -1, 2010	Jim	23/0	.,_525	,									
			extension trial 1337	1								1				1													